SCHEMBL14050927

SCHEMBL14050927

Cc1cnn2c(NCc3ccc(C(=O)N4CCSCC4)cc3)cc(-c3ccccc3F)nc12

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 3/20 0.53
▸ CDK2 P24941 7/20 0.51
▸ CCNA2 P20248 1/20 0.45
▸ CCNA1 P78396 1/20 0.45
▸ HPGD P15428 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ GPR39 O43194 1/20 0.41
▸ MAPK10 P53779 5/20 0.40
▸ MAP4K1 Q92918 1/20 0.39
▸ MAPK8 P45983 3/20 0.39
▸ TRPV3 Q8NET8 1/20 0.38
▸ CCNE1 P24864 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13305704 0.90 GSK3B (0.53) GSK3BCDK2CCNA2CCNA1HPGD
SCHEMBL12953964 0.90 GSK3B (0.67) GSK3BCDK2CCNA2CCNA1HPGD
SCHEMBL13305188 0.85 GSK3B (0.63) GSK3BCDK2CCNA2CCNA1GPR39
SCHEMBL13304910 0.85 GSK3B (0.60) GSK3BCDK2CCNA2CCNA1GPR39
SCHEMBL13305403 0.84 GSK3B (0.59) GSK3BCDK2CCNA2CCNA1GPR39
SCHEMBL12953772 0.83 GSK3B (0.68) GSK3BCDK2CCNA2CCNA1MAPK10
SCHEMBL13305706 0.83 GSK3B (0.54) GSK3BCDK2CCNA2CCNA1GPR39
SCHEMBL14050900 0.82 GSK3B (0.61) GSK3BCDK2CCNA2CCNA1GPR39
SCHEMBL12953767 0.82 GSK3B (0.69) GSK3BCDK2CCNA2CCNA1CCNE1
SCHEMBL13305398 0.82 GSK3B (0.54) GSK3BCDK2CCNA2CCNA1GPR39

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008130569-A1 NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS SCHERING CORPORATION (US) 2008-10-30 — — WO disclosed
Send feedback